Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tawanda Gumbo

Showing results (11-20 of 204) with videos related to

Pageof 21
Sort By:
Antimicrobial Agents and Chemotherapy|February 25, 2018
Reply to Zimenkov, "Mutation in <i>luxR</i> Family Transcriptional Regulator Rv0890c Is Not a Marker of Linezolid Resistance"Shashikant Srivastava, Tawanda Gumbo
The European Respiratory Journal|January 2, 2014
Integrating drug concentrations and minimum inhibitory concentrations with Bayesian-dose optimisation for multidrug-resistant tuberculosisShashikant Srivastava, Tawanda Gumbo
Antimicrobial Agents and Chemotherapy|May 31, 2018
Clofazimine for the Treatment of Mycobacterium kansasiiShashikant Srivastava, Tawanda Gumbo
Current Pharmaceutical Design|August 13, 2011
In vitro and in vivo modeling of tuberculosis drugs and its impact on optimization of doses and regimensShashikant Srivastava, Tawanda Gumbo
Microbiology Spectrum|April 21, 2026
Systematic and quantitative analyses of hollow fiber model of <i>Mycobacterium abscessus</i> lung disease studies and new dosing recommendationsShashikant Srivastava, Tawanda Gumbo
The European Respiratory Journal|April 2, 2021
Therapeutic drug monitoring and fluoroquinolones for multidrug-resistant tuberculosisShashikant Srivastava, Tawanda Gumbo
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 2, 2013
Reply to Moonan and Weis, Seaworth et al, and Nunn and PhillipsJotam G Pasipanodya, Tawanda Gumbo
The New England Journal of Medicine|November 1, 2002
AIDS orphansVictor M Moyo, Tawanda Gumbo
Antimicrobial Agents and Chemotherapy|May 5, 2010
Clinical and toxicodynamic evidence that high-dose pyrazinamide is not more hepatotoxic than the low doses currently usedJotam G Pasipanodya, Tawanda Gumbo
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 15, 2013
A meta-analysis of self-administered vs directly observed therapy effect on microbiologic failure, relapse, and acquired drug resistance in tuberculosis patientsJotam G Pasipanodya, Tawanda Gumbo
Pageof 21

Showing results (11-20 of 204) with videos related to

Sort By:
Pageof 21
Antimicrobial Agents and Chemotherapy|February 25, 2018
Reply to Zimenkov, "Mutation in <i>luxR</i> Family Transcriptional Regulator Rv0890c Is Not a Marker of Linezolid Resistance"Shashikant Srivastava, Tawanda Gumbo
The European Respiratory Journal|January 2, 2014
Integrating drug concentrations and minimum inhibitory concentrations with Bayesian-dose optimisation for multidrug-resistant tuberculosisShashikant Srivastava, Tawanda Gumbo
Antimicrobial Agents and Chemotherapy|May 31, 2018
Clofazimine for the Treatment of Mycobacterium kansasiiShashikant Srivastava, Tawanda Gumbo
Current Pharmaceutical Design|August 13, 2011
In vitro and in vivo modeling of tuberculosis drugs and its impact on optimization of doses and regimensShashikant Srivastava, Tawanda Gumbo
Microbiology Spectrum|April 21, 2026
Systematic and quantitative analyses of hollow fiber model of <i>Mycobacterium abscessus</i> lung disease studies and new dosing recommendationsShashikant Srivastava, Tawanda Gumbo
The European Respiratory Journal|April 2, 2021
Therapeutic drug monitoring and fluoroquinolones for multidrug-resistant tuberculosisShashikant Srivastava, Tawanda Gumbo
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 2, 2013
Reply to Moonan and Weis, Seaworth et al, and Nunn and PhillipsJotam G Pasipanodya, Tawanda Gumbo
The New England Journal of Medicine|November 1, 2002
AIDS orphansVictor M Moyo, Tawanda Gumbo
Antimicrobial Agents and Chemotherapy|May 5, 2010
Clinical and toxicodynamic evidence that high-dose pyrazinamide is not more hepatotoxic than the low doses currently usedJotam G Pasipanodya, Tawanda Gumbo
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 15, 2013
A meta-analysis of self-administered vs directly observed therapy effect on microbiologic failure, relapse, and acquired drug resistance in tuberculosis patientsJotam G Pasipanodya, Tawanda Gumbo
Pageof 21